Pond, S. K. | Search bioRxiv

bioRxiv2025

Standardizing RNA-seq Analysis of Fungal Pathogens Using BRC-Analytics and Agentic AI: A Candidozyma auris Case Study

Candidozyma auris has emerged as a critical global health threat due to multidrug resistance and healthcare-associated transmission. While RNA-seq has become the primary tool for studying C. auris pathogenesis, inconsistent use of reference genomes and bioinformatics tools complicate cross-study comparisons. Here we demonstrate how BRC-Analytics, a platform for pathogen genomics, combined with an agentic AI assistant, enables reproducible RNA-seq analysis. By re-analyzing data from two publications we achieved near-perfect correlation with published results despite annotation version differences. We addressed provenance challenges associated with using AI agents with Galaxy by forcing them to invoke Galaxys native tools rather than manipulating data directly. For custom analyses outside Galaxys toolset, we provide standalone JupyterLite notebooks that reproduce our analysis without AI involvement. This framework--combining AI-assisted automation with rigorous provenance tracking--establishes a template for standardized, reproducible fungal pathogen genomics. To the best of our knowledge, this is the first example of integration between public data repositories, reproducible analysis workflows, and agentic AI tools. Our subsequent efforts will focus on improving the seamlessness of this integration.

genomics↗

bioRxiv2025

HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation

HIV-1 persists as a latent reservoir during suppressive antiretroviral therapy (ART). Viral rebound occurs upon ART interruption, posing a challenge to cure efforts. Characterizing viral populations fuelling rebound is imperative to curing HIV-1. We used longitudinal samples collected pretherapy from women in the CAPRISA 002 cohort to create an evolutionary time- line to determine the pretherapy timepoint when the rebound virus originally entered the long- lived reservoir. Participants (N=10) were untreated for an average of 5 years then on ART for an average of 2 years before viral rebound (defined as >1000 RNA copies/ml). env sequences were used to characterize the longitudinal pre-ART evolving viral RNA population, the proviral DNA reservoir during ART, and viral RNA in the plasma during rebound. For each participant, between 1 and 3 major viral lineages were identified in the plasma during rebound. A total of 20 rebound virus lineages were examined for the 10 participants, and 19 were found to have entered the reservoir around the time of therapy initiation. The one lineage estimated to enter the reservoir more than a year before therapy was observed in a participant who was untreated for more than 8 years, yet retained moderate CD4 T cell counts. Analysis of the viral DNA reservoir, from which the rebound viruses emanated, revealed that while 95% of rebounding lineages dated to the year before ART initiation, only 61% of unique proviruses dated to that time period. Strikingly, for three participants with DNA reservoirs dominated by viruses from earlier in untreated infection, only 33% of unique proviruses dated to the year before ART initiation, yet 83% of rebounding lineages dated to that time. Our results show that rebound virus almost exclusively comes from the portion of the latent reservoir that formed around the time of therapy initiation, even when the reservoir is composed of diverse sequences from across the pre-ART time period. Author SummaryHIV-1 is maintained in a long-lived reservoir during suppressive therapy. Virus rebounds if therapy is discontinued. We found that in most cases rebound virus comes from a pool of viral sequences that entered the long-lived reservoir around the time of therapy initiation. While the viral DNA reservoir is on average also skewed toward sequences replicating around the time of therapy initiation, the rebound virus almost exclusively comes from this portion of the latent reservoir, even when the reservoir contained proviruses from much earlier in untreated infection. Thus, we hypothesize that there are features of the viruses forming the latent reservoir around the time of therapy initiation, or features of the host at that time, that select these viruses as initiators of rebound during therapy discontinuation.

microbiology↗